Asset Details
Do you wish to reserve the book?
Atrasentan in Patients with IgA Nephropathy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Atrasentan in Patients with IgA Nephropathy
Do you wish to request the book?
Atrasentan in Patients with IgA Nephropathy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Atrasentan in Patients with IgA Nephropathy
2025
Overview
In a prespecified interim analysis of a phase 3, randomized, controlled trial, the selective endothelin type A receptor antagonist atrasentan reduced proteinuria in patients with IgA nephropathy, without apparent safety issues.
Publisher
Massachusetts Medical Society
Subject
/ Allergy
/ Atrasentan - administration & dosage
/ Atrasentan - adverse effects
/ Biopsy
/ Edema
/ Endothelin A Receptor Antagonists - administration & dosage
/ Endothelin A Receptor Antagonists - adverse effects
/ Female
/ Glomerular Filtration Rate - drug effects
/ Glomerulonephritis, IGA - complications
/ Glomerulonephritis, IGA - diagnosis
/ Glomerulonephritis, IGA - drug therapy
/ Glomerulonephritis, IGA - urine
/ Humans
/ Male
/ Peptides
/ Placebos
/ Proteins
/ Sodium-glucose cotransporter
/ Urine
